A phase II RCT of lixisenatide in early PD, which was defined as patients recruited within 2 years of diagnosis, also demonstrated the promising disease-modifying effect of lixisenatide, particularly regarding motor disability
Symptoms like nausea, bloating, and constipation are most common during the initiation phase
We would like to extend our sincere thanks to Dr O Suchowersky, Director of the Movement Disorder Clinic, Department of Clinical Neurosciences, University of Calgary, Alberta, Canada for reviewing this paper and providing useful suggestions
The stomach is a harsh, acidic environment designed to break down proteins
No controlled human trials exist to establish safety during gestation or nursing